DE602005001688D1 - Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung - Google Patents

Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung

Info

Publication number
DE602005001688D1
DE602005001688D1 DE602005001688T DE602005001688T DE602005001688D1 DE 602005001688 D1 DE602005001688 D1 DE 602005001688D1 DE 602005001688 T DE602005001688 T DE 602005001688T DE 602005001688 T DE602005001688 T DE 602005001688T DE 602005001688 D1 DE602005001688 D1 DE 602005001688D1
Authority
DE
Germany
Prior art keywords
aldesleukin
sds
pharmaceutical use
preparation
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005001688T
Other languages
English (en)
Other versions
DE602005001688T2 (de
Inventor
Maninder Hora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE602005001688D1 publication Critical patent/DE602005001688D1/de
Application granted granted Critical
Publication of DE602005001688T2 publication Critical patent/DE602005001688T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005001688T 2005-02-07 2005-02-07 Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung Active DE602005001688T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05250680A EP1688146B1 (de) 2005-02-07 2005-02-07 Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung

Publications (2)

Publication Number Publication Date
DE602005001688D1 true DE602005001688D1 (de) 2007-08-30
DE602005001688T2 DE602005001688T2 (de) 2008-04-10

Family

ID=34940439

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005001688T Active DE602005001688T2 (de) 2005-02-07 2005-02-07 Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung

Country Status (10)

Country Link
EP (1) EP1688146B1 (de)
AT (1) ATE367167T1 (de)
CY (1) CY1108521T1 (de)
DE (1) DE602005001688T2 (de)
DK (1) DK1688146T3 (de)
ES (1) ES2289663T3 (de)
HR (1) HRP20070487T3 (de)
PL (1) PL1688146T3 (de)
PT (1) PT1688146E (de)
SI (1) SI1688146T1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010134091A1 (en) * 2009-05-20 2010-11-25 M/S. Provimi Animal Nutrition India Private Limited A process for preparation of a non-antibiotic growth promoter formula / product and its use in food animals
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CA2890258C (en) * 2012-11-02 2020-10-20 Cytuvax Composition comprising cytokine macro-aggregates
ES2807260T3 (es) 2014-08-11 2021-02-22 Delinia Inc Variantes de IL-2 modificadas que activan selectivamente las células T reguladoras para el tratamiento de enfermedades autoinmunes
CN108135841B (zh) * 2015-10-22 2024-03-05 艾尔图制药公司 Il-2的药物组合物
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EA201991142A1 (ru) 2016-11-08 2019-10-31 Варианты il-2 для лечения аутоиммунных заболеваний
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
EP3807305A4 (de) 2018-06-13 2022-04-20 Akron Biotechnology, LLC Verfahren zur herstellung von therapeutisch wirksamem aldesleukin, das in flüssigen pharmazeutischen zusammensetzungen hochstabil ist
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2

Also Published As

Publication number Publication date
HRP20070487T3 (en) 2007-12-31
DE602005001688T2 (de) 2008-04-10
CY1108521T1 (el) 2014-04-09
ATE367167T1 (de) 2007-08-15
SI1688146T1 (sl) 2007-12-31
ES2289663T3 (es) 2008-02-01
EP1688146A1 (de) 2006-08-09
EP1688146B1 (de) 2007-07-18
PT1688146E (pt) 2007-10-29
PL1688146T3 (pl) 2007-12-31
DK1688146T3 (da) 2007-11-05

Similar Documents

Publication Publication Date Title
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
DE602006016735D1 (de) Verfahren zur proliferation von stammzellen
DE602006017732D1 (de) Verfahren zur herstellung von lyophilisiertem piperacillin-natrium in kombination mit tazobactam-natrium, mit verbesserter stabilität nach der rekonstitution
CO6210752A2 (es) Compuestos biciclicos y uso como antidiabeticos
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
GB2441939A (en) Surgical membrane
HK1123733A1 (en) Viral hepatitis treatment
TW200700092A (en) Tigecycline compositions and methods of preparation
EA201791850A1 (ru) Борсодержащие малые молекулы
DE602006017995D1 (de) Verfahren zur herstellung von pregabalin und salzen daraus
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
DE602005016282D1 (de) Verfahren zur herstellung von camptothecin-derivaten
ATE385252T1 (de) Verfahren zur herstellung von granulatförmigen zusammensetzungen
DE602005026811D1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
ATE464289T1 (de) Neues verfahren zur herstellung von thoc
ATE482172T1 (de) Feste salzzubereitung, deren herstellung und verwendung
ATE451109T1 (de) Medizinische lösung; verfahren zur herstellung dieser lösung und ihre verwendung
DE50304242D1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
ATE420168T1 (de) Verfahren zur herstellung von extrachromosomalen nukleinsäuremolekülen
DE602005018941D1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: HORA, MANINDER, EMERYVILLE, CA 94608, US

8364 No opposition during term of opposition